Cytek Biosciences Stock Working Capital
| CTKB Stock | USD 4.03 0.08 1.95% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Cytek Biosciences' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 328.8 M | 311.4 M | |
| Change In Working Capital | 7.7 M | 8.1 M |
Cytek | Working Capital | Build AI portfolio with Cytek Stock |
Cytek Biosciences Company Working Capital Analysis
Cytek Biosciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Cytek Biosciences Working Capital | 328.78 M |
Most of Cytek Biosciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytek Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cytek Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Cytek Biosciences is extremely important. It helps to project a fair market value of Cytek Stock properly, considering its historical fundamentals such as Working Capital. Since Cytek Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytek Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytek Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Cytek Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Cytek Biosciences has a Working Capital of 328.78 M. This is 22.76% lower than that of the Health Care Equipment & Supplies sector and 75.84% lower than that of the Health Care industry. The working capital for all United States stocks is 77.76% higher than that of the company.
Cytek Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytek Biosciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytek Biosciences could also be used in its relative valuation, which is a method of valuing Cytek Biosciences by comparing valuation metrics of similar companies.Cytek Biosciences is currently under evaluation in working capital category among its peers.
Cytek Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cytek Biosciences from analyzing Cytek Biosciences' financial statements. These drivers represent accounts that assess Cytek Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytek Biosciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 2.3B | 1.8B | 1.1B | 1.1B | 1.2B | 1.9B |
Cytek Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cytek Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cytek Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Cytek Fundamentals
| Return On Equity | -0.0167 | ||||
| Return On Asset | -0.0377 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 274.37 M | ||||
| Shares Outstanding | 127.22 M | ||||
| Shares Owned By Insiders | 9.11 % | ||||
| Shares Owned By Institutions | 60.46 % | ||||
| Number Of Shares Shorted | 5.65 M | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 2.62 X | ||||
| Revenue | 200.45 M | ||||
| Gross Profit | 106.68 M | ||||
| EBITDA | (10.03 M) | ||||
| Net Income | (6.02 M) | ||||
| Cash And Equivalents | 349.89 M | ||||
| Cash Per Share | 2.60 X | ||||
| Total Debt | 17.02 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.97 X | ||||
| Cash Flow From Operations | 25.38 M | ||||
| Short Ratio | 4.54 X | ||||
| Earnings Per Share | (0.05) X | ||||
| Target Price | 5.75 | ||||
| Number Of Employees | 648 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 512.71 M | ||||
| Total Asset | 499.5 M | ||||
| Retained Earnings | (35.2 M) | ||||
| Working Capital | 328.78 M | ||||
| Net Asset | 499.5 M |
About Cytek Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytek Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytek Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytek Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:Check out Cytek Biosciences Piotroski F Score and Cytek Biosciences Altman Z Score analysis. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.735 | Earnings Share (0.05) | Revenue Per Share | Quarterly Revenue Growth (0.02) | Return On Assets |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.